Louis Reese is one of our two co-founders and is the Executive Chairman of the Company. Mr. Reese has served in this role for the Company since September 2014. Mr. Reese has also been a member of the executive committee of UBI since 2014. He was also a director of ShenLian Biotech from 2010 to 2014. Mr. Reese is also the co-founder of an investment and advisory firm with active investments in real estate, energy, hospitality and life sciences. His investments focus on achieving global impact in critical important areas through innovative models and approaches. He received his B.A. from University of Pennsylvania.
Mei Mei is Chief Executive Officer and Co-Founder of Vaxxinity and is also a member of the executive committee of United Biomedical, Inc. She has overseen the launch of one of the first endobody vaccines in the world and the successful spin-out of five companies, including Vaxxinity’s IPO on NASDAQ. She currently leads an active pipeline of chronic disease immunotherapeutic candidates including for Alzheimer’s, Parkinson’s, and hypercholesterolemia as well as variant-inclusive COVID booster. Mei Mei was formerly a consultant at McKinsey & Company where she advised pharmaceutical companies on strategic, operational and organizational issues. Mei Mei is also co-founder of an investment and advisory group with active investments in real estate, energy and life sciences. She has been named to Time 100 Next list, Fortune 40 under 40, and is a member of the Young Global Leaders of World Economic Forum. She holds a B.A. from University of Pennsylvania and her J.D. from Harvard Law School
Gregory R. Blatt is a director of the Company. Mr. Blatt has been a director of the Company since July 2021. Mr. Blatt recently served as Executive Chairman, and then Chairman and Chief Executive Officer, of Match Group, from 2013 through 2017, and as Executive Chairman, and then Chief Executive Officer, of Tinder, from 2015 through 2017. Prior to concurrently serving in those roles, Mr. Blatt was Chief Executive Officer of IAC from 2010 through 2013, Chief Executive Officer of Match.com from 2009 through 2010, General Counsel of IAC from 2003 through 2009 and General Counsel and EVP of Business Affairs at Martha Stewart Living Omnimedia from 1999 through 2003. Earlier in his career, Mr. Blatt worked as an associate at law firms Wachtell Lipton Rosen & Katz and Grubman Indursky and Schindler. Additionally, Mr. Blatt has served as a director on the board of directors for Interval Leisure Group, HSN, IAC and Match Group. Mr. Blatt received a B.A. from Colgate University and a J.D. from Columbia Law School.
James Chui is a director of the Company. Mr. Chui has been a director of the Company since the Reorganization and was previously a director of UNS since August 2019. He has also been a director of UBI since February 2020 and a director of United Biopharma (Holdings) Co. Ltd. (UBP’s parent company) since July 2018, both of which are privately-owned. Mr. Chui has also been the Executive Chairman of Tornado Global Hydrovacs Ltd., a company with a focus on hydrovac truck design and manufacturing, since September 2018, a director of Dynamic Technology Group, Inc. a technology solutions provider of innovative ride systems and dynamic structures, since September 2018 and the non-executive Chairman since November 2019 and a director of Beijing You Peng Technology Co., Ltd., a privately-owned internet TV platform provider in China, since April 2018 (having previously served as a director from November 2016 through May 2017). In addition to these roles, James has served as the Chairman, President and/or Chief Executive Officer of various investment holding companies for over two decades, including as the Chairman and Chief Executive Officer of Excellence Raise Overseas Limited since 2013. He received a B.Sc. in Engineering from Shanghai University of Science and Technology.
Peter Diamandis is a director of the Company. Dr. Diamandis has been a director of the Company since the Reorganization and was previously a director of COVAXX since March 2020. Dr. Diamandis has been the Chief Executive Officer of PHD Ventures, Inc., his personal holding company for his writing, speaking and consulting activities, since October 1993. Dr. Diamandis has started more than 24 companies in the areas of human longevity, space, venture capital and education, including as a co-founder of BOLD Capital Partners in 2015, a venture fund investing in exponential technologies, and as the founder and Executive Chairman of the XPRIZE Foundation, a non-profit foundation which, since 1996, has designed and operated large-scale incentive competitions for the development of new technologies that may help solve some of mankind’s major challenges. In the area of human longevity, he has helped found Human Longevity, Inc., for which he served as a director from 2013 until December 2018, Celularity Inc., for which he served as Vice Chairman from July 2017 to July 2021 and as a director starting in July 2021, and Fountain Therapeutic Services, Inc., for which he has served as Chairman since January 2019. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution founded in 2010 that counsels the world’s leaders on exponentially growing technologies. He also serves as a director of two special purpose acquisition companies: DPCM Capital, Inc., which completed its initial public offering in October 2020, and Software Acquisition Group Inc. II, which completed its initial public offering in September 2020. Dr. Diamandis is also a New York Times bestselling author. He earned degrees in Molecular Engineering and Aerospace Engineering from Massachusetts Institute of Technology and holds an M.D. from Harvard Medical School.
Mr. Hornig is currently Chairman of Xometry, an AI-driven platform for on-demand manufacturing of industrial parts and Co-Chairman (and Audit Chairman) of Healthwell Acquisition Corp., a special purpose acquisition company. Mr. Hornig is also Managing Partner and Co-Founder of The Seed Lab, an early-stage venture fund. From 2010-2016, Mr. Hornig was Senior Managing Director and COO of PineBridge Investments (formerly AIG Investment Management). Prior to joining PineBridge, Mr. Hornig spent 11 years at Credit Suisse Asset Management as Managing Director and Global COO. From 1993-1999, Mr. Hornig was Executive Vice President of Deutsche Bank Americas. Earlier in his career Mr. Hornig was Managing Director and COO of Wasserstein Perella & Co., worked in the M&A group of First Boston and was an Associate with the law firm of Skadden, Arps. During his career, Mr. Hornig has served as a Director of Forrester Research, Unity Mutual Life, Veridian Group, KBL Merger Corp IV, Office Tiger, Daily Candy and Merchants Preferred. Mr. Hornig received his A.B., J.D. and M.B.A. from Harvard University.